European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cassini, 2019, Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis, Lancet Infect Dis, 19, 56, 10.1016/S1473-3099(18)30605-4
Tacconelli, 2018, Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis, Lancet Infect Dis, 18, 318, 10.1016/S1473-3099(17)30753-3
2021
Clancy, 2019, Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae, Antimicrob Agents Chemother, 63, e01733, 10.1128/AAC.01733-19
Scudeller, 2021, Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli, Int J Antimicrob Agents, 57, 106344, 10.1016/j.ijantimicag.2021.106344
Zusman, 2013, Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems, Antimicrob Agents Chemother, 57, 5104, 10.1128/AAC.01230-13
Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, 339, b2700, 10.1136/bmj.b2700
Singer, 2016, The third international consensus definitions for sepsis and septic shock (Sepsis-3), JAMA, 315, 801, 10.1001/jama.2016.0287
Gutierrez-Gutierrez, 2016, A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae, Mayo Clin Proc, 91, 1362, 10.1016/j.mayocp.2016.06.024
Palacios-Baena, 2017, Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae, J Antimicrob Chemother, 72, 906
Kadri, 2018, Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents, Clin Infect Dis, 67, 1803
Wells, 2014
2017
Schünemann, 2013
Harris, 2018, Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial, JAMA, 320, 984, 10.1001/jama.2018.12163
Paterson, 2021, PRO: carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales, JAC Antimicrob Resist, 3, dlab013, 10.1093/jacamr/dlab013
Rodriguez-Bano, 2021, CON: carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales, JAC Antimicrob Resist, 3, dlaa112, 10.1093/jacamr/dlaa112
Marimuthu, 2019, Antecedent carbapenem exposure as a risk factor for non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae and carbapenemase-producing Enterobacteriaceae, Antimicrob Agents Chemother, 63, e00845, 10.1128/AAC.00845-19
Henderson, 2020, Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study, Clin Infect Dis, 73, e3842, 10.1093/cid/ciaa1479
Gutierrez-Gutierrez, 2016, A multinational, preregistered cohort study of beta-lactam/beta-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae, Antimicrob Agents Chemother, 60, 4159, 10.1128/AAC.00365-16
Harris, 2015, Comparable outcomes for beta-lactam/beta-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae, Antimicrob Resist Infect Control, 4, 14, 10.1186/s13756-015-0055-6
Ng, 2016, Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae, PLoS One, 11, 10.1371/journal.pone.0153696
Tamma, 2015, Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia, Clin Infect Dis, 60, 1319
Tsai, 2014, Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis, Diagn Microbiol Infect Dis, 80, 222, 10.1016/j.diagmicrobio.2014.07.006
Cheng, 2017, Piperacillin-tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC beta-lactamase-producing Enterobacteriaceae, Antimicrob Agents Chemother, 61, e00276, 10.1128/AAC.00276-17
Dizbay, 2016, Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam, Turk J Med Sci, 46, 1760, 10.3906/sag-1506-157
Gudiol, 2017, Efficacy of beta-lactam/beta-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae in hematological patients with neutropenia, Antimicrob Agents Chemother, 61, e00164, 10.1128/AAC.00164-17
Lee, 2010, Bacteremia due to extended-spectrum-beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy, Antimicrob Agents Chemother, 54, 3551, 10.1128/AAC.00055-10
Seo, 2017, Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli, BMC Infect Dis, 17, 404, 10.1186/s12879-017-2502-x
Yoon, 2017, Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli, Int J Antimicrob Agents, 49, 410, 10.1016/j.ijantimicag.2016.12.017
Nasir, 2019, Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy, BMC Res Notes, 12, 611, 10.1186/s13104-019-4648-7
Sharara, 2020, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum beta-lactamase-producing organisms?, Clin Infect Dis, 71, e331, 10.1093/cid/ciz1205
Xiao, 2019, Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016, Antimicrob Resist Infect Control, 8, 144, 10.1186/s13756-019-0599-y
Ko, 2018, Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study, Eur J Clin Microbiol Infect Dis, 37, 305, 10.1007/s10096-017-3133-2
Meini, 2018, Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward, Eur J Intern Med, 48, 50, 10.1016/j.ejim.2017.10.014
Namikawa, 2019, Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam, Diagn Microbiol Infect Dis, 94, 287, 10.1016/j.diagmicrobio.2019.01.018
Ray, 2018, Association of high mortality with extended-spectrum beta-lactamase (ESBL) positive cultures in community acquired infections, J Crit Care, 44, 255, 10.1016/j.jcrc.2017.10.036
Ofer-Friedman, 2015, Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae, Infect Control Hosp Epidemiol, 36, 981, 10.1017/ice.2015.101
Chaubey, 2010, Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae, BMC Res Notes, 3, 116, 10.1186/1756-0500-3-116
Chopra, 2012, Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli, Antimicrob Agents Chemother, 56, 3936, 10.1128/AAC.05419-11
Falcone, 2014, Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae, Ann Ig, 26, 293
Huang, 2006, Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella, J Microbiol Immunol Infect, 39, 496
To, 2013, Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity, Int J Infect Dis, 17, e120, 10.1016/j.ijid.2012.09.008
Meije, 2019, Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBL) or AmpC beta-lactamase: a propensity score study, Int J Antimicrob Agents, 54, 189, 10.1016/j.ijantimicag.2019.05.004
Palacios-Baena, 2017, Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: results from the INCREMENT Cohort, Clin Infect Dis, 65, 1615, 10.1093/cid/cix606
Paterson, 2004, Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases, Clin Infect Dis, 39, 31, 10.1086/420816
Collins, 2012, Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae, Antimicrob Agents Chemother, 56, 2173, 10.1128/AAC.05913-11
Wu, 2012, Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis, Int J Infect Dis, 16, e47, 10.1016/j.ijid.2011.09.019
Gutierrez-Gutierrez, 2016, Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study, J Antimicrob Chemother, 71, 1672, 10.1093/jac/dkv502
Lee, 2011, Carbapenem therapy for bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae, Diagn Microbiol Infect Dis, 70, 150, 10.1016/j.diagmicrobio.2010.12.008
Rattanaumpawan, 2017, Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial, BMC Infect Dis, 17, 183, 10.1186/s12879-017-2284-1
Lee, 2006, Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates, J Antimicrob Chemother, 58, 1074, 10.1093/jac/dkl381
Yang, 2012, Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis, BMC Infect Dis, 12, 206, 10.1186/1471-2334-12-206
Matsumura, 2015, Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli bacteremia, Antimicrob Agents Chemother, 59, 5107, 10.1128/AAC.00701-15
Fukuchi, 2016, Cefmetazole for bacteremia caused by ESBL-producing Enterobacteriaceae comparing with carbapenems, BMC Infect Dis, 16, 427, 10.1186/s12879-016-1770-1
Lee, 2013, Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters, Clin Infect Dis, 56, 488, 10.1093/cid/cis916
Tamma, 2013, The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae, Clin Infect Dis, 57, 781, 10.1093/cid/cit395
Blanchette, 2014, Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae, Scand J Infect Dis, 46, 803, 10.3109/00365548.2014.954262
Lee, 2015, Cefepime therapy for monomicrobial enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates, Antimicrob Agents Chemother, 59, 7558, 10.1128/AAC.01477-15
Siedner, 2014, Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia, Clin Infect Dis, 58, 1554, 10.1093/cid/ciu182
Wang, 2016, Cefepime therapy for cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia, Open Forum Infect Dis, 3, ofw132, 10.1093/ofid/ofw132
Endimiani, 2004, Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin, Clin Infect Dis, 38, 243, 10.1086/380645
Lo, 2017, Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae, J Microbiol Immunol Infect, 50, 355, 10.1016/j.jmii.2015.08.012
Punjabi, 2019, Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs β-lactams as step-down therapy for Enterobacteriaceae bacteremia: systematic review and meta-analysis, Open Forum Infect Dis, 6, ofz364, 10.1093/ofid/ofz364
Zohar, 2020, Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae, J Antimicrob Chemother, 75, 458
Kang, 2013, Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy, Scand J Infect Dis, 45, 519, 10.3109/00365548.2013.775479
Kaye, 2019, Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2/3 randomized trial, Clin Infect Dis, 69, 2045, 10.1093/cid/ciz181
2020
Veve, 2016, Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infections, Int J Antimicrob Agents, 48, 56, 10.1016/j.ijantimicag.2016.04.014
Wagenlehner, 2019, Once-daily plazomicin for complicated urinary tract infections, N Engl J Med, 380, 729, 10.1056/NEJMoa1801467
Beaucaire, 2000, Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally?, Clin Microbiol Infect, 6, 355, 10.1046/j.1469-0691.2000.00105.x
Doi, 2013, The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae, Int J Infect Dis, 17, e159, 10.1016/j.ijid.2012.09.010
Pilmis, 2014, Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae, Eur J Clin Microbiol Infect Dis, 33, 1263, 10.1007/s10096-014-2094-y
Senard, 2020, Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis, Eur J Clin Microbiol Infect Dis, 39, 121, 10.1007/s10096-019-03701-0
Kim, 2018, Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae, Int J Antimicrob Agents, 51, 155, 10.1016/j.ijantimicag.2017.09.013
Delory, 2021, Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case–control study, Int J Antimicrob Agents, 58, 106361, 10.1016/j.ijantimicag.2021.106361
Lee, 2013, Outcome of antimicrobial therapy of pediatric urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae, Infect Chemother, 45, 415, 10.3947/ic.2013.45.4.415
Park, 2014, The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli, J Antimicrob Chemother, 69, 2848, 10.1093/jac/dku215
Vazquez, 2012, Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study, Curr Med Res Opin, 28, 1921, 10.1185/03007995.2012.748653
Wagenlehner, 2016, Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program, Clin Infect Dis, 63, 754, 10.1093/cid/ciw378
Wagenlehner, 2015, Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI), The Lancet, 385, 1949, 10.1016/S0140-6736(14)62220-0
Freire, 2010, Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia, Diagn Microbiol Infect Dis, 68, 140, 10.1016/j.diagmicrobio.2010.05.012
Zanetti, 2003, Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study, Antimicrob Agents Chemother, 47, 3442, 10.1128/AAC.47.11.3442-3447.2003
Torres, 2018, Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial, Lancet Infect Dis, 18, 285, 10.1016/S1473-3099(17)30747-8
Kollef, 2019, Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial, Lancet Infect Dis, 19, 1299, 10.1016/S1473-3099(19)30403-7
Goethaert, 2006, High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients, Clin Microbiol Infect, 12, 56, 10.1111/j.1469-0691.2005.01290.x
FDA
Mazuski, 2016, Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program, Clin Infect Dis, 62, 1380, 10.1093/cid/ciw133
Solomkin, 2015, Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI), Clin Infect Dis [Internet], 60, 1462, 10.1093/cid/civ097
Solomkin, 2017, Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial, JAMA Surg, 152, 224, 10.1001/jamasurg.2016.4237
van Duin, 2018, Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae, Clin Infect Dis, 66, 163, 10.1093/cid/cix783
Shields, 2017, Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia, Antimicrob Agents Chemother, 61, e00883, 10.1128/AAC.00883-17
Caston, 2017, Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients, Int J Infect Dis, 59, 118, 10.1016/j.ijid.2017.03.021
Tumbarello, 2019, Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae, Clin Infect Dis, 68, 355, 10.1093/cid/ciy492
Alraddadi, 2019, Efficacy of ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae, BMC Infect Dis, 19, 772, 10.1186/s12879-019-4409-1
Shields, 2016, Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections, Clin Infect Dis, 63, 1615, 10.1093/cid/ciw636
Both, 2017, Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate, J Antimicrob Chemother, 72, 2483, 10.1093/jac/dkx179
Humphries, 2015, First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate, Antimicrob Agents Chemother, 59, 6605, 10.1128/AAC.01165-15
Raisanen, 2018, Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, Euro Surveill, 24, 1900256
Zhang, 2020, Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China, Clin Microbiol Infect, 26, 124e1, 10.1016/j.cmi.2019.08.020
Livermore, 2015, In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase, Antimicrob Agents Chemother, 59, 5324, 10.1128/AAC.00678-15
Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla(KPC-3) mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61, e02097, 10.1128/AAC.02097-16
Tumbarello, 2021, Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study, Clin Infect Dis, 73, 1664, 10.1093/cid/ciab176
Voulgari, 2020, Detection in two hospitals of transferable ceftazidime-avibactam resistance in Klebsiella pneumoniae due to a novel VEB beta-lactamase variant with a Lys234Arg substitution, Greece, 2019, Euro Surveill, 25, 1900766, 10.2807/1560-7917.ES.2020.25.2.1900766
Galani, 2020, Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019, Euro Surveill, 25, 2000028, 10.2807/1560-7917.ES.2020.25.3.2000028
Petty, 2018, Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae, Infect Drug Resist, 11, 1461, 10.2147/IDR.S150447
Wunderink, 2018, Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II Randomized Clinical Trial, Infect Dis Ther, 7, 439, 10.1007/s40121-018-0214-1
Livermore, 2013, Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa, J Antimicrob Chemother, 68, 2286
Lucasti, 2016, Phase 2, Dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection, Antimicrob Agents Chemother, 60, 6234, 10.1128/AAC.00633-16
Sims, 2017, Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections, J Antimicrob Chemother, 72, 2616, 10.1093/jac/dkx139
Titov, 2020, A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study), Clin Infect Dis, 73, e4539, 10.1093/cid/ciaa803
2021
Motsch, 2020, RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections, Clin Infect Dis, 70, 1799, 10.1093/cid/ciz530
Portsmouth, 2018, Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial, Lancet Infect Dis, 18, 1319, 10.1016/S1473-3099(18)30554-1
Wunderink, 2021, Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial, Lancet Infect Dis, 21, 213, 10.1016/S1473-3099(20)30731-3
Bassetti, 2021, Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial, Lancet Infect Dis, 21, 226, 10.1016/S1473-3099(20)30796-9
Poeylaut-Palena, 2007, A minimalistic approach to identify substrate binding features in B1 Metallo-beta-lactamases, Bioorg Med Chem Lett, 17, 5171, 10.1016/j.bmcl.2007.06.089
Falcone, 2016, Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae, Clin Microbiol Infect, 22, 444, 10.1016/j.cmi.2016.01.016
Messina, 2016, Hospital readmissions in patients with carbapenem-resistant Klebsiella pneumoniae, Infect Control Hosp Epidemiol, 37, 281, 10.1017/ice.2015.298
van Duin, 2015, Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae, J Antimicrob Chemother, 70, 1203, 10.1093/jac/dku495
Satlin, 2011, Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine, Antimicrob Agents Chemother, 55, 5893, 10.1128/AAC.00387-11
Gonzalez-Padilla, 2015, Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae, J Antimicrob Chemother, 70, 905, 10.1093/jac/dku432
Freire, 2019, The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae, Eur J Clin Microbiol Infect Dis, 38, 755, 10.1007/s10096-019-03468-4
Liang, 2019, Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection, Braz J Infect Dis, 23, 60, 10.1016/j.bjid.2018.12.004
Nguyen, 2010, Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes, Diagn Microbiol Infect Dis, 67, 180, 10.1016/j.diagmicrobio.2010.02.001
Ji, 2015, Cefepime combined with amoxicillin/clavulanic acid: a new choice for the KPC-producing K. pneumoniae infection, Int J Infect Dis, 38, 108, 10.1016/j.ijid.2015.07.024
Ku, 2012, Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections, Am J Infect Control, 40, 983, 10.1016/j.ajic.2011.12.014
Garbati, 2016, Infections due to carbapenem resistant Enterobacteriaceae among Saudi Arabian hospitalized patients: a matched case–control study, Biomed Res Int, 2016, 3961684, 10.1155/2016/3961684
De Pascale, 2014, High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria, Crit Care, 18, R90, 10.1186/cc13858
Geng, 2018, High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study, Medicine (Balt), 97, 10.1097/MD.0000000000009961
Michalopoulos, 2010, Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation, Clin Microbiol Infect, 16, 184, 10.1111/j.1469-0691.2009.02921.x
Pontikis, 2014, Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria, Int J Antimicrob Agents, 43, 52, 10.1016/j.ijantimicag.2013.09.010
Karageorgopoulos, 2012, Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases, J Antimicrob Chemother, 67, 2777, 10.1093/jac/dks270
Liao, 2017, Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae, Exp Ther Med, 13, 1003, 10.3892/etm.2017.4046
Luterbach, 2019, The role of trimethoprim/sulfamethoxazole in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae, Open Forum Infect Dis, 6, ofy351, 10.1093/ofid/ofy351
Solomkin, 2019, IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections, Clin Infect Dis, 69, 921, 10.1093/cid/ciy1029
McKinnell, 2019, Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae, N Engl J Med, 380, 791, 10.1056/NEJMc1807634
Bergamasco, 2012, Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation, Transpl Infect Dis, 14, 198, 10.1111/j.1399-3062.2011.00688.x
Capone, 2013, High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality, Clin Microbiol Infect, 19, E23, 10.1111/1469-0691.12070
Chang, 2015, Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan, J Microbiol Immunol Infect, 48, 219, 10.1016/j.jmii.2014.05.010
Crusio, 2014, Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy, Scand J Infect Dis, 46, 1, 10.3109/00365548.2013.844350
Daikos, 2014, Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems, Antimicrob Agents Chemother, 58, 2322, 10.1128/AAC.02166-13
de Maio Carrilho, 2016, A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome, BMC Infect Dis, 16, 629, 10.1186/s12879-016-1979-z
Diaz, 2016, Clinical characteristics of carbapenem-resistant Klebsiella pneumoniae infections in ill and colonized children in Colombia, Pediatr Infect Dis J, 35, 237, 10.1097/INF.0000000000000987
Freire, 2015, Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients, Eur J Clin Microbiol Infect Dis, 34, 277, 10.1007/s10096-014-2233-5
Gomez-Simmonds, 2016, Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections, Antimicrob Agents Chemother, 60, 3601, 10.1128/AAC.03007-15
Gutierrez-Gutierrez, 2017, Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study, Lancet Infect Dis, 17, 726, 10.1016/S1473-3099(17)30228-1
Katsiari, 2015, Carbapenem-resistant Klebsiella pneumoniae infections in a Greek intensive care unit: molecular characterisation and treatment challenges, J Glob Antimicrob Resist, 3, 123, 10.1016/j.jgar.2015.01.006
King, 2017, Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections, Antimicrob Agents Chemother, 61, e00449, 10.1128/AAC.00449-17
Kontopidou, 2014, Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options, Clin Microbiol Infect, 20, O117, 10.1111/1469-0691.12341
Machuca, 2017, Mortality associated with bacteremia due to colistin-resistant Klebsiella pneumoniae with high-level meropenem resistance: importance of combination therapy without colistin and carbapenems, Antimicrob Agents Chemother, 61, e00406, 10.1128/AAC.00406-17
Malande, 2016, Invasive carbapenem-resistant Enterobacteriaceae infection at a paediatric hospital: a case series, S Afr Med J, 106, 877
Nelson, 2015, Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods, Antimicrob Agents Chemother, 59, 7000, 10.1128/AAC.00844-15
Papadimitriou-Olivgeris, 2017, Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality, Eur J Clin Microbiol Infect Dis, 36, 1125, 10.1007/s10096-017-2899-6
Paul, 2018, Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial, Lancet Infect Dis, 18, 391, 10.1016/S1473-3099(18)30099-9
Qureshi, 2012, Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens, Antimicrob Agents Chemother, 56, 2108, 10.1128/AAC.06268-11
Shields, 2016, Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae, Antimicrob Agents Chemother, 60, 3187, 10.1128/AAC.02638-15
Tofas, 2016, Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases, Int J Antimicrob Agents, 47, 335, 10.1016/j.ijantimicag.2016.01.011
Tumbarello, 2015, Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study, J Antimicrob Chemother, 70, 2133, 10.1093/jac/dkv086
Tuon, 2017, Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae, Braz J Infect Dis, 21, 1, 10.1016/j.bjid.2016.09.008
Villegas, 2016, Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing Enterobacteriaceae in seven Latin American countries, PLoS One, 11, 10.1371/journal.pone.0154092
Zarkotou, 2011, Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment, Clin Microbiol Infect, 17, 1798, 10.1111/j.1469-0691.2011.03514.x
Medeiros, 2019, Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection, Int J Antimicrob Agents, 53, 152, 10.1016/j.ijantimicag.2018.10.010
Su, 2018, Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan, Eur J Clin Microbiol Infect Dis, 37, 651, 10.1007/s10096-017-3156-8
Lin, 2019, Appropriate treatment for bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae and Escherichia coli: a nationwide multicenter study in Taiwan, Open Forum Infect Dis, 6, ofy336, 10.1093/ofid/ofy336
Errico, 2019, Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy, Clin Microbiol Infect, 25, 203, 10.1016/j.cmi.2018.05.003
Zusman, 2017, Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis, J Antimicrob Chemother, 72, 29, 10.1093/jac/dkw377
Schmid, 2019, Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: systematic review and meta-analysis, Sci Rep, 9, 15290, 10.1038/s41598-019-51711-x
Wang, 2017, The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis, Ann Clin Microbiol Antimicrob, 16, 24, 10.1186/s12941-017-0199-8
Giamarellou, 2011, Pharmacokinetic and pharmacodynamic evaluation of tigecycline, Expert Opin Drug Metab Toxicol, 7, 1459, 10.1517/17425255.2011.623126
de Oliveira, 2015, Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins, Clin Microb Infect, 21, 179.e1, 10.1016/j.cmi.2014.07.010
Cheng, 2015, Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study, Crit Care Med, 43, 1194, 10.1097/CCM.0000000000000933
2021
Giannella, 2018, Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection, Int J Antimicrob Agents, 51, 2448, 10.1016/j.ijantimicag.2017.08.019
Erdem, 2020, In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains, Antimicrob Resist Infect Control, 9, 70, 10.1186/s13756-020-00727-4
Oliva, 2016, Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae, Clin Microbiol Infect, 22, 147, 10.1016/j.cmi.2015.09.014
Cancelli, 2018, Role of double-carbapenem regimen in the treatment of infections due to carbapenemase producing carbapenem-resistant Enterobacteriaceae: a single-center, observational study, Biomed Res Int, 2018, 2785696, 10.1155/2018/2785696
De Pascale, 2017, Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case–control study, Crit Care, 21, 173, 10.1186/s13054-017-1769-z
Venugopalan, 2017, Double carbapenem therapy (DCT) for bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP): from test tube to clinical practice, Infect Dis (Lond), 49, 867, 10.1080/23744235.2017.1350880
Shields, 2018, Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections, Antimicrob Agents Chemother, 62, 10.1128/AAC.02497-17
De la Calle, 2019, Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam, Int J Antimicrob Agents, 53, 520, 10.1016/j.ijantimicag.2018.11.015
Tumbarello, 2021, Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study, Clin Infect Dis, 73, 1664, 10.1093/cid/ciab176
Karlowsky, 2017, In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015, Antimicrob Agents Chemother, 61, e00472, 10.1128/AAC.00472-17
Sader, 2018, Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates, Antimicrob Agents Chemother, 62, 1, 10.1128/AAC.01856-17
Shaw, 2018, Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection, J Antimicrob Chemother, 73, 1104, 10.1093/jac/dkx496
Falcone, 2021, Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-beta-lactamase-producing Enterobacterales, Clin Infect Dis, 72, 1871, 10.1093/cid/ciaa586
Gottig, 2019, Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo, J Antimicrob Chemother, 74, 3211, 10.1093/jac/dkz330
Pogue, 2020, Ceftolozane/Tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa, Clin Infect Dis, 71, 304, 10.1093/cid/ciz816
Apisarnthanarak, 2012, Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin, Int J Antimicrob Agents, 39, 271, 10.1016/j.ijantimicag.2011.11.012
Akajagbor, 2013, Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center, Clin Infect Dis, 57, 1300, 10.1093/cid/cit453
Khawcharoenporn, 2014, Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia, Int J Antimicrob Agents, 43, 378, 10.1016/j.ijantimicag.2014.01.016
Rigatto, 2015, Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections, Antimicrob Agents Chemother, 59, 6575, 10.1128/AAC.00494-15
Falagas, 2010, Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients, Int J Antimicrob Agents, 35, 194, 10.1016/j.ijantimicag.2009.10.005
Diaz-Canestro, 2018, Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands, Eur J Clin Microbiol Infect Dis, 37, 2191, 10.1007/s10096-018-3361-0
Landersdorfer, 2017, Substantial targeting advantage achieved by pulmonary administration of colistin methanesulfonate in a large-animal model, Antimicrob Agents Chemother, 61, e01934, 10.1128/AAC.01934-16
Boisson, 2014, Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients, Antimicrob Agents Chemother, 58, 7331, 10.1128/AAC.03510-14
Betrosian, 2008, Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, J Infect, 56, 432
Khalili, 2018, Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia, J Comp Eff Res, 7, 901, 10.2217/cer-2018-0037
Oliveira, 2008, Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp, J Antimicrob Chemother, 61, 1369, 10.1093/jac/dkn128
Zalts, 2016, Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam, Am J Ther, 23, e78, 10.1097/MJT.0b013e3182a32df3
Mosaed, 2018, Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter, Iran J Pharm Res, 17, 206
Chuang, 2014, Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis, BMC Infect Dis, 14, 102, 10.1186/1471-2334-14-102
Kim, 2016, Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients, PLoS One, 11
Kwon, 2014, Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii, Biol Pharm Bull, 37, 340, 10.1248/bpb.b13-00109
De Pascale, 2020, Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections, Ann Intensive Care, 10, 94, 10.1186/s13613-020-00715-2
Lee, 2013, Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections, Eur J Clin Microbiol Infect Dis, 32, 1211, 10.1007/s10096-013-1870-4
Ye, 2016, Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex, BMC Infect Dis, 16, 374, 10.1186/s12879-016-1717-6
Liang, 2018, Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Clin Microbiol Infect, 24, 908e1, 10.1016/j.cmi.2017.10.033
Niu, 2019, Comparison of tigecycline or cefoperazone/sulbactam therapy for bloodstream infection due to carbapenem-resistant Acinetobacter baumannii, Antimicrob Resist Infect Control, 8, 52, 10.1186/s13756-019-0502-x
Zhou, 2019, Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia: a retrospective study from a Chinese hospital, Medicine (Balt), 98
Shionogi, 2019
Chan, 2010, Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia, J Intensive Care Med, 25, 343, 10.1177/0885066610377975
Gounden, 2009, Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections, BMC Infect Dis, 9, 26, 10.1186/1471-2334-9-26
Holloway, 2006, Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit, Ann Pharmacother, 40, 1939, 10.1345/aph.1H353
Mohammadi, 2017, Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii: a systematic review and meta-analysis, Open Microbiol J, 11, 63, 10.2174/1874285801711010063
O'Hara, 2013, Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains, Antimicrob Agents Chemother, 57, 2103, 10.1128/AAC.02501-12
Lenhard, 2016, Synergistic combinations of polymyxins, Int J Antimicrob Agents, 48, 607, 10.1016/j.ijantimicag.2016.09.014
Otto, 2019, An alternative strategy for combination therapy: interactions between polymyxin B and non-antibiotics, Int J Antimicrob Agents, 53, 34, 10.1016/j.ijantimicag.2018.09.003
Vardakas, 2019, Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: a systematic review, J Glob Antimicrob Resist, 17, 250, 10.1016/j.jgar.2019.01.004
Kalin, 2014, Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, Infection, 42, 37, 10.1007/s15010-013-0495-y
Poulakou, 2009, Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens, J Infect, 58, 273
Sirijatuphat, 2014, Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections, Antimicrob Agents Chemother, 58, 5598, 10.1128/AAC.02435-13
Hernandez-Torres, 2012, Multidrug and carbapenem-resistant Acinetobacter baumannii infections: factors associated with mortality, Med Clin (Barc), 138, 650, 10.1016/j.medcli.2011.06.024
Lim, 2011, The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections, J Korean Med Sci, 26, 325, 10.3346/jkms.2011.26.3.325
Tasbakan, 2011, Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia?, J Chemother, 23, 345
Tseng, 2007, Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii, Diagn Microbiol Infect Dis, 59, 181, 10.1016/j.diagmicrobio.2007.04.024
Ye, 2011, The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii, J Infect, 63, 351
Amat, 2018, The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii, Clin Microbiol Infect, 24, 630, 10.1016/j.cmi.2017.09.016
Batirel, 2014, Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections, Eur J Clin Microbiol Infect Dis, 33, 1311, 10.1007/s10096-014-2070-6
Makris, 2018, Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study, Indian J Crit Care Med, 22, 67, 10.4103/ijccm.IJCCM_302_17
Dickstein, 2019, Treatment outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial, Clin Infect Dis, 69, 769, 10.1093/cid/ciy988
Durante-Mangoni, 2013, Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin Infect Dis, 57, 349, 10.1093/cid/cit253
Garnacho-Montero, 2013, Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii, Chemotherapy, 59, 225, 10.1159/000356004
Park, 2019, Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: a randomised controlled trial, J Glob Antimicrob Resist, 17, 66, 10.1016/j.jgar.2018.11.016
Petrosillo, 2014, Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria, Antimicrob Agents Chemother, 58, 851, 10.1128/AAC.00871-13
Freire, 2016, Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia, Clin Microbiol Infect, 22, 352, 10.1016/j.cmi.2015.12.010
Kuo, 2007, Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome, Clin Microbiol Infect, 13, 196, 10.1111/j.1469-0691.2006.01601.x
Yilmaz, 2015, Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia, J Infect Dev Ctries, 9, 476, 10.3855/jidc.6195
Aydemir, 2013, Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia, Epidemiol Infect, 141, 1214, 10.1017/S095026881200194X
Lopez-Cortes, 2014, Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort, J Antimicrob Chemother, 69, 3119, 10.1093/jac/dku233
Shields, 2012, Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients, PLoS One, 7, 10.1371/journal.pone.0052349
Simsek, 2012, Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy?, Indian J Med Microbiol, 30, 448, 10.4103/0255-0857.103767
Farooq, 2014, Extended-spectrum beta-lactamase-producing Escherichia coli isolation among older adults: epidemiology and outcomes, Am J Infect Control, 42, 565, 10.1016/j.ajic.2014.01.015
Freeman, 2012, Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes, Int J Infect Dis, 16, e371, 10.1016/j.ijid.2012.01.008
Rello, 2017, Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases, Clin Microbiol Infect, 23, 629, 10.1016/j.cmi.2017.04.011
Tamma, 2021
Paterson, 2004, International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections, Ann Intern Med, 140, 26, 10.7326/0003-4819-140-1-200401060-00008
Solomkin, 2015, Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI), Clin Infect Dis, 60, 1462, 10.1093/cid/civ097